We at Cellogen Therapeutics use advanced cellular engineering methods and gene therapy-based approaches to find curative treatment for various hematological malignancies, solid tumors and hemoglobinopathies. We have conceptualised and designed state-of-the-art third and fourth generation CAR constructs (CAR T-cell therapies) for Blood cancers such as leukaemia, lymphoma. We have also developed genetic therapies for Beta-Thalassemia and sickle cell disease, the two most common debilitating blood disorders. Over the last decade, the impressive clinical outcome of cell and gene-based therapies has given a new hope for patients suffering from life-threatening diseases. Cellular and gene therapies have transformed the therapeutic landscape by providing long-lasting and permanent cure. However, these therapeutic modalities are currently expensive and limited to a few countries. Our vision is to make these revolutionary therapies available to masses, particularly for the patients in India where the majority of the patients cannot afford the cost. We will provide a convenient and cost-effective solution by indigenously manufacturing these therapeutic modalities.